Innoviva (NASDAQ:INVA) will be releasing its earnings data after the market closes on Wednesday, February 7th. Analysts expect Innoviva to post earnings of $0.38 per share for the quarter.
Shares of Innoviva (INVA) opened at $15.03 on Wednesday. Innoviva has a one year low of $10.30 and a one year high of $16.11. The stock has a market cap of $1,620.00, a price-to-earnings ratio of 19.03 and a beta of 2.52. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of -2.59.
In other Innoviva news, VP George B. Abercrombie sold 5,215 shares of Innoviva stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $13.26, for a total transaction of $69,150.90. Following the sale, the vice president now owns 263,866 shares of the company’s stock, valued at approximately $3,498,863.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Eric Desparbes sold 15,285 shares of Innoviva stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $13.28, for a total transaction of $202,984.80. Following the sale, the chief financial officer now directly owns 337,027 shares in the company, valued at approximately $4,475,718.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,522 shares of company stock worth $429,985. 1.60% of the stock is currently owned by corporate insiders.
A number of research firms recently issued reports on INVA. Robert W. Baird reissued a “hold” rating and issued a $13.00 price target on shares of Innoviva in a research note on Tuesday, October 24th. BidaskClub raised shares of Innoviva from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Deutsche Bank assumed coverage on shares of Innoviva in a research note on Monday, November 20th. They issued a “hold” rating and a $13.00 price target on the stock. Zacks Investment Research cut shares of Innoviva from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $8.00 target price (up previously from $7.00) on shares of Innoviva in a research note on Friday, October 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $13.50.
COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/31/innoviva-inva-to-release-earnings-on-wednesday.html.
Innoviva Company Profile
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.